Gyre Therapeutics posted Q2 2025 revenue of $26.8 million and net income of $1.6 million. Earnings were supported by the successful launch of Etorel and continued rollout of Contiva in the PRC. Operating income declined year-over-year due to higher marketing and administrative costs.

Gyre Therapeutics reported a revenue of $25.5 million and a net income of $2.9 million for the third quarter ended September 30, 2024. The company's cash and cash equivalents totaled $15.9 million as of September 30, 2024.

Gyre Therapeutics reported revenues of $25.2 million and a net income of $4.5 million for the second quarter ended June 30, 2024. The company received NMPA approval for avatrombopag maleate tablets and IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension.

Gyre Therapeutics reported revenues of $27.2 million for Q1 2024, driven by sales of ETUARY, and income from operations was $8.1 million. The company's Phase 3 clinical trial for F351 remains on track, with data anticipated by early 2025.

Gyre Therapeutics reported full year 2023 financial results, highlighting a transformational year with the acquisition of F351 and strong ETUARY sales. The company is progressing with clinical trials for F351 and F573, and expects to report data from the Phase 3 trial evaluating F351 for CHB-associated liver fibrosis in the PRC by early 2025.

Beijing Continent Pharmaceuticals Co., Ltd. reported an increase in revenue and net profit for the six months ended June 30, 2023. Revenue increased to RMB 379,265 thousands from RMB 312,673 thousands. Net profit increased to RMB 81,198 thousands from RMB 63,876 thousands.

Catalyst Biosciences reported a net income of $51.6 million for the second quarter of 2022, driven by the sale of its complement portfolio to Vertex Pharmaceuticals for $60.0 million. The company is now focused on distributing available cash to stockholders.

Catalyst Biosciences reported a net loss of $14.5 million for the first quarter ended March 31, 2022. The company regained the rights to CB 2782-PEG and decreased headcount by over 70% as part of cost reduction efforts.

Catalyst Biosciences reported a net loss of $20.3 million for Q4 2021. The company is focusing on complement therapeutics, including CB 2782-PEG and CB 4332, and is exploring strategic alternatives while implementing cost reduction measures.

Catalyst Biosciences announced a strategic decision to halt the clinical development of MarzAA and focus on its complement therapeutics and protease medicines platform. The company reported a net loss of $25.2 million for the third quarter of 2021.

Catalyst Biosciences reported a net loss of $19.9 million for the second quarter of 2021. The company is advancing its complement and hemostasis programs, with key milestones including the initiation of the ConFIrm study for CFI deficiency and progress in the Crimson 1 Phase 3 registrational study of MarzAA.